Aricept 30-week, Phase III trialsADAS-cog Results

Study week

Placebowashout

Clinical improvement

Clinical decline

4.0

0

3.5

3.0

2.5

2.0

1.5

1.0

0.5

0.0

–0.5

–1.0

–1.5

–2.0

–2.5

6

12

18

30

Endpoint

US Study† Multinational Study‡

Placebo

Aricept:

5 mg/day

10 mg/day

**

**

**

**

**

**

**

**

**

**

**

**

**

ITT-LOCF analysis; **p?0.001 for Aricept versus placebo

†Rogers et al. Neurology 1998;50:136–145; ‡Burns et al. Dement Geriatr Cogn Disord 1999;10:237–244

Least squares mean change frombaseline (±SE)

**

Previous slide

Next slide

Back to first slide

View graphic version